Search Results - "Rubinstein, L V"

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials by JOHNSON, J. I, DECKER, S, SAUSVILLE, E. A, ZAHAREVITZ, D, RUBINSTEIN, L. V, VENDITTI, J. M, SCHEPARTZ, S, KALYANDRUG, S, CHRISTIAN, M, ARBUCK, S, HOLLINGSHEAD, M

“…An analysis of the activity of compounds tested in pre-clinical in vivo and in vitro assays by the National Cancer Institute's Developmental Therapeutics…”
Get full text

Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q by Jhaveri, K.L., Wang, X.V., Makker, V., Luoh, S.-W., Mitchell, E.P., Zwiebel, J.A., Sharon, E., Gray, R.J., Li, S., McShane, L.M., Rubinstein, L.V., Patton, D., Williams, P.M., Hamilton, S.R., Conley, B.A., Arteaga, C.L., Harris, L.N., O’Dwyer, P.J., Chen, A.P., Flaherty, K.T.

“…The National Cancer Institute—Molecular Analysis for Therapy Choice (NCI-MATCH) is a national precision medicine study incorporating centralized genomic…”
Get full text

Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines by Rubinstein, L V, Shoemaker, R H, Paull, K D, Simon, R M, Tosini, S, Skehan, P, Scudiero, D A, Monks, A, Boyd, M R

“…The National Cancer Institute (NCI) is implementing a large-scale in vitro drug-screening program that requires a very efficient automated assay of drug…”
Get more information

MR imaging evaluation of endometrial carcinoma: results of an NCI cooperative study by Hricak, H, Rubinstein, L V, Gherman, G M, Karstaedt, N

“…A prospective study to assess the usefulness of magnetic resonance (MR) imaging in the evaluation of endometrial carcinoma was undertaken by five institutions…”
Get more information

NCI-MATCH Arms N & P: Phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/del) or PTEN protein loss by Janku, F, Jegede, O, Puhalla, S L, Konstantinopoulos, P, Meric-Bernstam, F, Mitchell, E P, Zwiebel, J A, McShane, L M, Li, S, Rubinstein, L V, Doyle, L A, Patton, D, Conley, B A, O'Dwyer, P J, Harris, L N, Arteaga, C, Williams, P M, Hamilton, S R, Chen, A P, Flaherty, K T

Get full text

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial by Mansfield, A. S., Wei, Z., Mehra, R., Shaw, A. T., Lieu, C. H., Forde, P. M., Drilon, A. E., Mitchell, E. P., Wright, J. J., Takebe, N., Sharon, E., Hovelson, D., Tomlins, S., Zeng, J., Poorman, K., Malik, N., Gray, R. J., Li, S., McShane, L. M., Rubinstein, L. V., Patton, D., Williams, P. M., Hamilton, S. R., Conley, B. A., Arteaga, C. L., Harris, L. N., O’Dwyer, P. J., Chen, A. P., Flaherty, K. T.

“…The NCI-MATCH was designed to characterize the efficacy of targeted therapies in histology-agnostic driver mutation-positive malignancies. Sub-protocols F and…”
Get full text

Therapeutic studies by Rubinstein, L V

“…This article discusses the problems in basic design, conduct, and interpretation associated with phases I, II, and III of the cancer clinical trials and…”
Get more information

Neural Computing in Cancer Drug Development: Predicting Mechanism of Action by Weinstein, John N., Kohn, Kurt W., Grever, Michael R., Viswanadhan, Vellarkad N., Rubinstein, Lawrence V., Monks, Anne P., Scudiero, Dominic A., Welch, Lester, Koutsoukos, Antonis D., Chiausa, August J., Paull, Kenneth D.

“…Described here are neural networks capable of predicting a drug's mechanism of action from its pattern of activity against a panel of 60 malignant cell lines…”
Get full text

Preclinical antitumor activity of temozolomide in mice : efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea by PLOWMAN, J, WAUD, W. R, KOUTSOUKOS, A. D, RUBINSTEIN, L. V, MOORE, T. D, GREVER, M. R

“…Temozolomide, a methylating agent with clinical activity against brain tumors, demonstrated excellent antitumor activity following p.o. administration to…”
Get full text

Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies by Feld, R, Rubinstein, L V, Weisenberger, T H

“…The Lung Cancer Study Group recently completed a double-blind adjuvant immunotherapy study, in which 473 patients with resected stage I non-small-cell lung…”
Get more information

Enhanced sensitivity to 1-β-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes by KOO, H.-M, MONKS, A, ZARBL, H, VANDE WOUDE, G. F, MIKHEEV, A, RUBINSTEIN, L. V, GRAY-GOODRICH, M, MCWILLIAMS, M. J, ALVORD, W. G, OIE, H. K, GAZDAR, A. F, PAULL, K. D

“…We used human tumor cell lines from the National Cancer Institute's In Vitro Antineoplastic Drug Screen to assess whether sensitivity to any of the…”
Get full text

Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening by LIN WU, SMYTHE, A. M, SHOEMAKER, R. H, STINSON, S. F, MULLENDORE, L. A, MONKS, A, SCUDIERO, D. A, PAULL, K. D, KOUTSOUKOS, A. D, RUBINSTEIN, L. V, BOYD, M. R

“…Disease-oriented panels of human tumor cell lines used by the National Cancer Institute for large-scale in vitro anticancer drug screening were evaluated for…”
Get full text

Markov Models for Covariate Dependence of Binary Sequences by Muenz, Larry R., Rubinstein, Lawrence V.

“…Suppose that a heterogeneous group of individuals is followed over time and that each individual can be in state 0 or state 1 at each time point. The sequence…”
Get full text

Predictive statistics and artificial intelligence in the U.S. National Cancer Institute's Drug Discovery Program for Cancer and AIDS by Weinstein, J N, Myers, T, Buolamwini, J, Raghavan, K, van Osdol, W, Licht, J, Viswanadhan, V N, Kohn, K W, Rubinstein, L V, Koutsoukos, A D

“…The National Cancer Institute's drug discovery program screens more than 20,000 chemical compounds and natural products a year for activity against a panel of…”
Get more information

Artists' offspring by Rubinstein, L. V, Koutsoukos, A. D

Get full text

Vaginal Clear Cell Adenocarcinoma in the United States by Trimble, Edward L., Rubinstein, Lawrence V., Menck, Herman R., Hankey, Benjamin F., Kosary, Carol, Giusti, Ruthann M.

“…We elected to examine available information from several sources to approximate the annual number of cases of vaginal adenocarcinoma in the United States for…”
Get full text

Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma by Sznol, M, Clark, J W, Smith, 2nd, J W, Steis, R G, Urba, W J, Rubinstein, L V, VanderMolen, L A, Janik, J, Sharfman, W H, Fenton, R G

“…Experiments in animal tumor models suggest that the antitumor effects of interleukin-2 (IL-2) or IL-2 in combination with lymphokine-activated killer (LAK)…”
Get more information

Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1K by Kalinsky, K., Zihan, W., McCourt, C., Mitchell, E.P., Wright, J.J., Doyle, L.A., Gray, R.J., Wang, V., McShane, L.M., Rubinstein, L.V., Patton, D., Williams, P.M., Hamilton, S.R., Conley, B.A., Arteaga, C.A., Harris, L.N., O’Dwyer, P.J., Chen, A.P., Flaherty, K.T.

Get full text

Application of molecular profiling in clinical trials for advanced metastatic cancers by Kummar, Shivaani, Williams, P Mickey, Lih, Chih-Jian, Polley, Eric C, Chen, Alice P, Rubinstein, Larry V, Zhao, Yingdong, Simon, Richard M, Conley, Barbara A, Doroshow, James H

“…There is growing interest in the application of molecular profiling, including sequencing, genotyping, and/or mRNA expression profiling, to the analysis of…”
Get full text

Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A by Reckamp, K., Song, Z., Gettinger, S., Mitchell, E.P., Wright, J.J., Moscow, J.A., Gray, R.J., Wang, V., McShane, L.M., Rubinstein, L.V., Patton, D.R., Williams, P.M., Hamilton, S.R., Conley, B.A., Arteaga, C.L., Harris, L.N., O’Dwyer, P.J., Chen, A.P., Flaherty, K.T.

Get full text